Conditional approval: Discussion points from the PSI Conditional Approval Expert Group

Pharmaceutical Statistics

Volumn 7, Issue 4, 2008, Pages 263-269

  Carroll, Kevin ^a,b   Ross, Hilary Chaudri ^a,c   Evans, Dan ^a,d   France, Lesley ^a,b   Hemmings, Rob ^a,e   Hughes, Sara ^a,f   Lynn, Frances ^a,e   Mahoney, Paul ^a,e   Phillips, Alan ^a,g  

^a PSI Discussion Group on Conditional Approval

^b ASTRAZENECA   (United Kingdom)

^c Novartis Pharma AG   (Switzerland)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e MHRA ^*  (United Kingdom)

^f GLAXOSMITHKLINE   (United Kingdom)

^g ICON CLINICAL RESEARCH   (United States)

Author keywords

Conditional approval; HIV; Oncology

Indexed keywords

ARTICLE; CLINICAL RESEARCH; CONDITIONAL APPROVAL; CONSULTATION; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; EUROPE; HUMAN IMMUNODEFICIENCY VIRUS; INFORMATION DISSEMINATION; LAW; MEDICAL EXPERT; ONCOLOGY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; SYSTEMATIC ERROR;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; EXPERT TESTIMONY; HUMANS;

EID: 57849114811     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.309     Document Type: Article

References (6)

1. Dagher R, Johnson J, Williams G, Keegan P, Pazdur R. Accelerated approval of oncology products: a decade of experience. Journal of the National Cancer Institute 2004; 96(20):1500-1509.
2. Sutent Scientific Discussion. Available at: www.emea.europa.eu/humandocs/ pdfs/EPAR/sutent/06870en6.pdf (accessed 21.06.2007).
3. Food and Drug Administration, Centre for Drug Evaluation and Research. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Electronic document available at: http://www.fda.gov/cder/guidance/7478fnl.htm (accessed 21.06.2007).
4. Food and Drug Administration, Centre for Drug Evaluation and Research. Guidance for Industry: Antiretroviral Drugs using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval. Electronic document available at: http://www.fda.gov/cder/ guidance/3647fnl.htm (accessed 21.06.2007).
5. European Medicines Agency, Committee for Medicinal Products. Guideline on the Clinical Development of Medicinal Products for the Treatment of HIV Infection (CPMP/EWP/633/02, Rev. 1). Electronic document available at: http://www.emea.europa.eu/pdfs/human/ewp/063302en.pdf (accessed 25.04.2007).
6. Laessig KA, Lewis LL, Hammerstrom TS. Tenofovir DF and emtricitabine vs. zidovudine and lamivudine: letter to the editor. New England Journal of Medicine 2006; 254(23):2506-2507.